Genoplan

New York, United States Founded: 2014 • Age: 12 yrs
Developer of genetic test kits for health analysis
Annual revenue - Latest available
Total funding $17.2M 4 rounds
Employees - Tracked headcount
Investors 8 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Genoplan

Genoplan is a company based in New York (United States) founded in 2014. Genoplan has raised $17.25 million across 4 funding rounds from investors including GC Genome, GC Holdings and PIA Investment Management. Genoplan operates in a competitive market with competitors including 23andMe, Color, Veritas Genetics, InformedDNA and Arivale, among others.

  • Headquarter New York, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $17.25 M (USD)

    in 4 rounds

  • Latest Funding Round
    $13 M (USD), Series B

    Sep 02, 2018

  • Investors
    GC Genome

    & 7 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Genoplan

Headcount 10-50
Employee Profiles 3
Board Members and Advisors 5
Employee Profiles
People
Brian Byungkyu Kang
Founder & CEO
People
Byung-Chul Lee
Chief Scientific Officer | Head of RnD Division

Unlock access to complete

Board Members and Advisors
people
Byungjoon Choi
Advisor
people
Jaewoo Moon
Advisor
people
Honghui Won
Advisor
people
Hie Lim Kim
Advisor

Unlock access to complete

Funding Insights of Genoplan

Genoplan has successfully raised a total of $17.25M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $13.0M
  • First Round

    (01 Mar 2015)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2018 Amount Series B - Genoplan Valuation GC Holdings
Mar, 2016 Amount Series A - Genoplan Valuation

investors

Jun, 2015 Amount Seed - Genoplan Valuation SparkLabs

Investors in Genoplan

Genoplan has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GC Genome, GC Holdings and PIA Investment Management.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Dayli Partners is focused on bio-healthcare and fintech investments.
Founded Year Domain Location
Investments are directed toward semiconductors, telecommunications, software, and medical sectors.
Founded Year Domain Location

Investments & Acquisitions by Genoplan

Investments

Financial Statements - Genoplan

Genoplan Comparisons

+
Add Comparison
Available on Premium

Competitors of Genoplan

Genoplan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 23andMe, Color, Veritas Genetics, InformedDNA and Arivale, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
domain founded_year HQ Location
Cancer care is delivered through a virtual clinic by Color.
domain founded_year HQ Location
Genetic testing products for health risks and traits are offered.
domain founded_year HQ Location
Network of genetics experts provided to assist patients and providers.
domain founded_year HQ Location
Provider of direct-to-consumer genetic testing.
domain founded_year HQ Location
Provider of a platform for gene analysis to determine genetic diseases and drug response

Latest news on Genoplan

Frequently Asked Questions about Genoplan

Genoplan was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Genoplan is headquartered in New York, United States. It is registered at New York, New York, United States.

Genoplan is a funded company, having raised a total of $17.25M across 4 funding rounds to date.

Genoplan was founded in 2014 and is based in New York, United States. Operations focus on the genetic testing sector, where saliva samples are collected and analyzed for DNA-based health insights. Tailored lifestyle recommendations are generated, covering areas such as diet, health foods, workouts, and cosmetics, to support individual wellness decisions.

Genoplan's top competitors include 23andMe, Veritas Genetics and Color.

Genoplan has 8 investors. Key investors include GC Genome, GC Holdings, PIA Investment Management, Dayli Partners, and Wonik.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available